PHASE II TRIAL ASSESS SFTY OF IMNOSPRSN W/DRAWAL IN LIVER TRNSPLNT RECIP W/HEP C

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a prospective multicenter, open-label, randomized trial in which participants with hepatitis C-related liver failure undergo liver transplantation and receive immunosuppression induction with tacrolimus and corticosteroids. Corticosteroids are tapered in the 3 months after transplantation and tacrolimus is continued. Participants are regularly assessed for recurrence of hepatitis and for evidence of allograft rejection. One year after transplantation, participants suitable for withdrawal are randomly assigned to immunosuppression withdrawal or maintenance. Participants assigned to withdrawal undergo a scheduled taper over 1 year.